These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 33171706)

  • 21. A systems biology approach to antimalarial drug discovery.
    Cortopassi WA; Celmar Costa Franca T; Krettli AU
    Expert Opin Drug Discov; 2018 Jul; 13(7):617-626. PubMed ID: 29737894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting malaria protein kinases.
    Cassiano GC; Tavella TA; Nascimento MN; Rodrigues DA; Cravo PVL; Andrade CH; Costa FTM
    Adv Protein Chem Struct Biol; 2021; 124():225-274. PubMed ID: 33632466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Supporting malaria elimination with 21st century antimalarial agent drug discovery.
    Diagana TT
    Drug Discov Today; 2015 Oct; 20(10):1265-70. PubMed ID: 26103616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimalarial drug discovery - the path towards eradication.
    Burrows JN; Burlot E; Campo B; Cherbuin S; Jeanneret S; Leroy D; Spangenberg T; Waterson D; Wells TN; Willis P
    Parasitology; 2014 Jan; 141(1):128-39. PubMed ID: 23863111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical examination of approaches exploited to assess the effectiveness of transmission-blocking drugs for malaria.
    Wadi I; Anvikar AR; Nath M; Pillai CR; Sinha A; Valecha N
    Future Med Chem; 2018 Nov; 10(22):2619-2639. PubMed ID: 30499742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leveraging cell cycle analysis in anticancer drug discovery to identify novel plasmodial drug targets.
    Kozlov S; Waters NC; Chavchich M
    Infect Disord Drug Targets; 2010 Jun; 10(3):165-90. PubMed ID: 20334621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasmodial Hsp40s: New Avenues for Antimalarial Drug Discovery.
    Daniyan MO; Blatch GL
    Curr Pharm Des; 2017 Nov; 23(30):4555-4570. PubMed ID: 28120726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.
    Ashton TD; Devine SM; Möhrle JJ; Laleu B; Burrows JN; Charman SA; Creek DJ; Sleebs BE
    J Med Chem; 2019 Dec; 62(23):10526-10562. PubMed ID: 31385706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Falcipain inhibitors as potential therapeutics for resistant strains of malaria: a patent review.
    Mane UR; Gupta RC; Nadkarni SS; Giridhar RR; Naik PP; Yadav MR
    Expert Opin Ther Pat; 2013 Feb; 23(2):165-87. PubMed ID: 23228154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to antimalarial compounds: methods and applications.
    Witkowski B; Berry A; Benoit-Vical F
    Drug Resist Updat; 2009; 12(1-2):42-50. PubMed ID: 19285915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel molecular targets for antimalarial drug development.
    Sahu NK; Sahu S; Kohli DV
    Chem Biol Drug Des; 2008 Apr; 71(4):287-97. PubMed ID: 18298458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current therapies and future possibilities for drug development against liver-stage malaria.
    Raphemot R; Posfai D; Derbyshire ER
    J Clin Invest; 2016 Jun; 126(6):2013-20. PubMed ID: 27249674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Commit, hide and escape: the story of Plasmodium gametocytes.
    Beri D; Balan B; Tatu U
    Parasitology; 2018 Nov; 145(13):1772-1782. PubMed ID: 30008275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antimalarial screening landscape-looking beyond the asexual blood stage.
    Yahiya S; Rueda-Zubiaurre A; Delves MJ; Fuchter MJ; Baum J
    Curr Opin Chem Biol; 2019 Jun; 50():1-9. PubMed ID: 30875617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug.
    da Cruz FP; Martin C; Buchholz K; Lafuente-Monasterio MJ; Rodrigues T; Sönnichsen B; Moreira R; Gamo FJ; Marti M; Mota MM; Hannus M; Prudêncio M
    J Infect Dis; 2012 Apr; 205(8):1278-86. PubMed ID: 22396598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRIMALDDI: platform technologies and novel anti-malarial drug targets.
    Vial H; Taramelli D; Boulton IC; Ward SA; Doerig C; Chibale K
    Malar J; 2013 Nov; 12():396. PubMed ID: 24498961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites.
    Delves M; Plouffe D; Scheurer C; Meister S; Wittlin S; Winzeler EA; Sinden RE; Leroy D
    PLoS Med; 2012 Feb; 9(2):e1001169. PubMed ID: 22363211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-Nitro styrylquinoline is an antimalarial inhibiting multiple stages of Plasmodium falciparum asexual life cycle.
    Roberts BF; Zheng Y; Cleaveleand J; Lee S; Lee E; Ayong L; Yuan Y; Chakrabarti D
    Int J Parasitol Drugs Drug Resist; 2017 Apr; 7(1):120-129. PubMed ID: 28285258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957.
    Miguel-Blanco C; Murithi JM; Benavente ED; Angrisano F; Sala KA; van Schalkwyk DA; Vanaerschot M; Schwach F; Fuchter MJ; Billker O; Sutherland CJ; Campino SG; Clark TG; Blagborough AM; Fidock DA; Herreros E; Gamo FJ; Baum J; Delves MJ
    Sci Rep; 2021 Jan; 11(1):1888. PubMed ID: 33479319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.